Contrary to popular belief, GW0742 is not a new SARM, but just like Cardarine, belongs to a class of PPAR delta agonists.

It is rumored that the only reason why GW0742 was developed in the first place was to extend the patent GlaxoSmithKline has on Cardarine. When we look at the chemical structure of GW0742, we can see that there is only a small difference in one atom between the two compounds. This tells us that GW0742 might not be that much different from Cardarine and that their effects may in fact be similar.

GW0742 works just like any PPAR delta agonist out there. It basically has two jobs: Turning our fat into an energy source and increasing the oxidative capacity of our muscles.

This means that GW0742 should technically be amazing when it comes to increasing endurance in athletes. However, no studies, not even on rats have been done to find out the link between GW0742 and endurance. GW0742 also improves insulin sensitivity which should lower the occurrence of type II diabetes. This has been proven on rats by the following study. Sadly, as of now, no human trials exist with GW0742. The compound is still new, so we can expect a lot more human trials in the future.